Derivation of mimetic γδ T cells endowed with cancer recognition receptors from reprogrammed γδ T cell
Open Access
- 9 May 2019
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (5) , e0216815
Abstract
Using induced pluripotent stem cells (iPSCs) to derive chimeric antigen receptor-modified T (CAR-T) cells has great industrial potential. A previous study used αβ T cell-derived CAR-modified iPSCs to produce CAR-T cells. However, these αβ T cells are restricted to autologous use and only recognize single cancer antigen. To make CAR-T alternative for allogeneic use, we reprogrammed γδ T cell into iPSCs (γδ T-iPSCs) to circumvent the risk of graft-versus-host disease. To target multiple cancer-associated antigens, we used an “NK cell-promoting” protocol to differentiate γδ T-iPSCs and to induce expression of natural killer receptors (NKRs). Through such two-step strategy, mimetic γδ T cells endowed with an array of NKRs and thus designated as “γδ natural killer T (γδ NKT) cells” were derived. With no/low-level expression of inhibitory killer cell immunoglobulin-like receptors (KIRs) and immune checkpoint receptors, γδ NKT cells may provide a potent “off-the-shelf” cytotoxic cell source to recognize multiple ubiquitous antigens in a broad spectrum of cancers.Keywords
This publication has 40 references indexed in Scilit:
- Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic CapabilitiesAnnual Review of Immunology, 2017
- The Principles of Engineering Immune Cells to Treat CancerCell, 2017
- Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphomaAmerican Journal of Hematology, 2016
- CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticityNature Communications, 2016
- Advances in understanding the pathogenesis of graft‐versus‐host diseaseBritish Journal of Haematology, 2016
- Clinical Applications of Gamma Delta T Cells with Multivalent ImmunityFrontiers in Immunology, 2014
- Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapyNature Biotechnology, 2013
- Human Vγ9Vδ2 T cells: promising new leads for immunotherapy of infections and tumorsCurrent Opinion in Immunology, 2006
- γδ T cells: A new frontier for immunotherapy?Transplantation and Cellular Therapy, 2005
- Human γδ T cells as mediators of chimaeric‐receptor redirected anti‐tumour immunityBritish Journal of Haematology, 2004